Hypoxia Pathway Proteins are Master Regulators of Erythropoiesis.
Deepika WattsDiana GaeteDiego RodriguezDavid HoogewijsMartina RaunerSundary SormendiBen WielockxPublished in: International journal of molecular sciences (2020)
Erythropoiesis is a complex process driving the production of red blood cells. During homeostasis, adult erythropoiesis takes place in the bone marrow and is tightly controlled by erythropoietin (EPO), a central hormone mainly produced in renal EPO-producing cells. The expression of EPO is strictly regulated by local changes in oxygen partial pressure (pO2) as under-deprived oxygen (hypoxia); the transcription factor hypoxia-inducible factor-2 induces EPO. However, erythropoiesis regulation extends beyond the well-established hypoxia-inducible factor (HIF)-EPO axis and involves processes modulated by other hypoxia pathway proteins (HPPs), including proteins involved in iron metabolism. The importance of a number of these factors is evident as their altered expression has been associated with various anemia-related disorders, including chronic kidney disease. Eventually, our emerging understanding of HPPs and their regulatory feedback will be instrumental in developing specific therapies for anemic patients and beyond.
Keyphrases
- chronic kidney disease
- end stage renal disease
- transcription factor
- poor prognosis
- endothelial cells
- bone marrow
- red blood cell
- peritoneal dialysis
- induced apoptosis
- ejection fraction
- newly diagnosed
- mesenchymal stem cells
- prognostic factors
- cell cycle arrest
- dna binding
- long non coding rna
- oxidative stress
- endoplasmic reticulum stress
- recombinant human
- young adults
- genome wide identification
- cell death
- childhood cancer